FVA-33008-05540
3 vaccinations
1 coded response
18 check-ins
1 free-text entry
0 call cases
- Sex
- Male
- Age at first dose
- 0-4
- ZIP prefix
- 604 / IL
- Registered
- 2022-06-24
- Relationship
- Child or adolescent in my care
- Guardian
- U7B-29342-90333
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2022-06-23
Dose 1 — Pfizer-BioNTech
-
2022-06-24
Registered in v-safe
- 2022-06-24
- 2022-06-25
- 2022-06-26
- 2022-06-27
- 2022-06-29
- 2022-06-30
- 2022-07-07
- 2022-07-16
-
2022-07-24
Dose 2 — Pfizer-BioNTech
-
2022-09-22
Dose 3 — Pfizer-BioNTech
- 2022-09-22
- 2022-09-27
- 2022-09-29
- 2022-10-06
- 2022-10-13
- 2022-10-20
- 2022-10-27
- 2022-11-03
-
2022-12-22
Survey response — 3 months, dose 3, under 3MedDRA: Nasopharyngitis, Rhinorrhoea — Feeling: GoodFree text: Cold. Runny nose.MedDRA releases: 2024-11 · check-in free text available
- 2023-03-23
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2022-06-23 | Pfizer-BioNTech | No |
| 2 | 2022-07-24 | Pfizer-BioNTech | No |
| 3 | 2022-09-22 | Pfizer-BioNTech | No |
Free text
Release 12 (Under 3) — 3 months, dose 3, under 3
Symptoms: Cold. Runny nose.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Nasopharyngitis | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release